<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01374438</url>
  </required_header>
  <id_info>
    <org_study_id>MSDC-0160-C006</org_study_id>
    <nct_id>NCT01374438</nct_id>
  </id_info>
  <brief_title>3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition &amp; Safety in Subjects With Alzheimer's Disease</brief_title>
  <official_title>A 3-month Randomized, Double-Blind, Placebo-Controlled, Feasibility Study to Evaluate the Effects of MSDC-0160 on Brain Glucose Utilization, Cognition, Safety and Tolerability in Older Persons With Mild Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metabolic Solutions Development Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metabolic Solutions Development Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of 150 mg MSDC-0160 taken daily for 90 days compared to
      the effect of placebo on changes in brain glucose utilization using FDG-PET and cognition in
      older persons with mild Alzheimer's disease. Safety and tolerability of MSDC-0160 in this
      population will also be studied. These results will be used to design larger studies of
      MSDC-0160 in persons with mild Alzheimer's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific objective is to examine the feasibility of conducting future large scale studies
      on the efficacy of MSDC-0160 in persons with mild Alzheimer's disease. Efficacy and safety
      will be assessed as follows:

        1. Estimate the effect size of 150 mg daily MSDC-0160 versus placebo on 3-month change in
           brain glucose utilization using FDG-PET pre-specified regions of interest analysis. The
           a priori regions of interest (ROI) will include five bilateral regions: posterior
           cingulate, parietal cortex (angular gyrus), lateral temporal cortex, medial temporal
           cortex, and anterior cingulate-medial frontal cortex.

        2. Estimate the effect size of MSDC-0160 versus placebo on 3-month change in brain glucose
           utilization, using FDG-PET voxel-based analysis.

        3. Estimate the effect size of MSDC-0160 treatment versus placebo on 3-month change in
           cognitive function as determined by global cognitive function on a neuropsychological
           battery of 19 tests.

        4. Estimate the effect size of MSDC-0160 versus placebo on 3-month change in cognitive
           function as determined by the ADAS-Cog subscale.

        5. Estimate the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item
           executive function scale.

        6. Explore whether baseline levels of peripheral inflammatory biomarkers (HMW adiponectin,
           TNFα, IL-6, hsCRP, and FFA) or genotypes including, but not limited to, the
           apolipoprotein ε4 allele explain the heterogeneity in baseline level of brain glucose
           utilization and, in MSDC-0160 users, 3-month brain glucose utilization.

        7. Explore whether changes in peripheral inflammatory biomarkers correlate with changes in
           3-month brain glucose utilization in MSDC-0160 users.

        8. Investigate the safety of MSDC-0160 versus placebo using reports of early study
           termination and adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum</measure>
    <time_frame>Days 1(baseline) and 91</time_frame>
    <description>Investigate the effect of 150 mg daily MSDC-0160 vs placebo on 3-month change in brain glucose utilization using FDG-PET pre-specified regions of interest analysis referenced to cerebellum, including five bilateral regions: posterior cingulate, parietal cortex (angular gyrus), lateral temporal cortex, medial temporal cortex, and anterior cingulate-medial frontal cortex. Results are reported as Standardized Uptake Value Ratios. A change from baseline in the metabolic rate of glucose that is ≥0 indicates maintenance of brain glucose utilization, whereas values &lt;0 indicate a decline in brain glucose utilization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Global Cognitive Function Tests</measure>
    <time_frame>Days 1 (baseline) and 91</time_frame>
    <description>Change from baseline in cognitive function, as determined by global cognitive function on a neuropsychological battery of 19 tests, following 3 months treatment with MSDC-0160 versus placebo. A summary measure of global cognitive function was constructed by converting raw scores from 19 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort, Neuroepidemiology. 2005;25(4):163-175.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cognitive Function as Determined by the ADAS-Cog Subscale</measure>
    <time_frame>Days 1 (baseline) and 91</time_frame>
    <description>Alzheimer's Disease Assessment Scale - Cognitive Subscale, an assessment of cognitive ability. Scores on 11 individual tasks were summed to produce the reported total score, with a possible range of 0 (no impairment) to 70 (severe impairment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cognitive Function as Estimate With the Executive Function Scale</measure>
    <time_frame>Days 1 (baseline) and 91</time_frame>
    <description>Estimate of the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale. A summary measure of executive function was constructed by converting raw scores from 9 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort, Neuroepidemiology. 2005;25(4):163-175.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HMW Adiponectin of MSDC-0160 or Placebo Over 12 Weeks</measure>
    <time_frame>Days 1(baseline) and 91</time_frame>
    <description>Estimate the effect of 150 mg daily MSDC-0160 versus placebo on levels of high molecular weight adiponectin. Increases in HMW adiponectin suggest improved insulin sensitivity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>MSDC-0160 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MSDC tablets contained in #00 capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets contained in #00 capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSDC-0160</intervention_name>
    <description>MSDC-0160 150 mg capsules given once daily for 90 days</description>
    <arm_group_label>MSDC-0160 capsules</arm_group_label>
    <other_name>Mitoglitazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules given once daily for 90 days</description>
    <arm_group_label>Placebo capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or females 55-85 years of age.

          2. Females should be either postmenopausal or surgically sterilized. Males with female
             partners of child-bearing potential must use contraception if engaging in sexual
             intercourse.

          3. Diagnosis of probable Alzheimer's disease based on NIA-AA criteria with MMSE scores of
             20 or greater.

          4. Willing and able to take part in up to six study visits over a 5-month period, with
             the support of a caregiver as needed.

          5. Willing and able to sign an informed consent document indicating understanding the
             purpose of and procedures required for the study and willingness to participate in the
             study, with the support of a caregiver as needed.

        Exclusion Criteria:

          1. Diagnosis of diabetes, including use of anti-diabetic medications, or fasting plasma
             glucose &gt;125 mg/dl or Hemoglobin A1c&gt;6.4%.

          2. Unable to participate in FDG-PET scanning, including:

               -  Inability to cooperate/claustrophobia (no sedation offered for this protocol).

               -  Inability to lie still on the scanner bed for 40 minutes.

               -  Total radiation dose exposure to the subject in any given year exceeds the limits
                  of annual and total dose commitment of 50 mSv (5 REMs). The two FDG-PET scans
                  will result in an approximate exposure of 10 mSv (1 REM).

          3. Diagnosis of significant neurological/psychiatric disease other than AD, including,
             but not limited to, any of the following: vascular dementia according to NINDS-AIREN
             criteria, space occupying cerebral lesion, Huntington's Disease, Parkinson's Disease,
             normal pressure hydrocephalus, and seizures.

          4. History of heart failure (including CHF).

          5. Previous cardiovascular event (myocardial infarct, by-pass surgery, or PTCA) within
             the past 6 months prior to screening.

          6. Inability to undergo a clinical (1.5T) MRI of the brain without contrast and lack of a
             usable (less the 12 months prior to screening) MRI on record. Contraindications to
             undergoing an MRI of the brain include, but are not limited to, pacemakers;
             implantable cardioverter defibrillators; cochlear implants; cerebral aneurysm clips;
             implanted infusion pumps; implanted nerve stimulators; metallic splinters in the eye;
             and, other magnetic, electronic or mechanical implants or clinical findings that in
             the judgment of the investigator would pose a potential hazard in combination with
             MRI.

          7. ALT and/or AST levels that are twice the upper limit of normal; bilirubin levels that
             exceed 2 mg/dL; serum creatinine &gt;1.5 mg/dL in men or &gt; 1.4 mg/dL in women.

          8. Current or history of severe or unstable disorder (medical or psychiatric) requiring
             treatment that may make the subject unlikely to complete the study.

          9. Malignancy (other than non-melanoma skin cancer) within the last 5 years.

         10. Known history of HIV, hepatitis B, or hepatitis C.

         11. Blood pressure greater than 160/100 mmHg. Subjects with elevated BP will be allowed at
             the discretion of the principal investigator. Individuals with hypertension must have
             been stabilized to the current treatment regimen for at least 6 weeks prior to
             screening and not need adjustments to their treatment regimen during the entire study
             period.

         12. Change in other medications to treat Alzheimer's disease within 3 months prior to
             screening. Change in medication to treat other conditions within 6 weeks prior to
             screening or during the study period.

         13. Known or suspected intolerance or hypersensitivity to the study drugs, closely related
             compounds, or any of their stated ingredients.

         14. History of alcohol or drug abuse within 6 months of screening.

         15. Have participated in an investigational study or received an investigational drug
             within 30 days or 5 half-lives (whichever is longer) prior to study drug
             administration.

         16. Single 12-lead ECG demonstrating a QTcB &gt;450 msec or other clinically significant
             finding at screening. A single repeat ECG may be done at the investigator's
             discretion.

         17. Any surgical or medical condition which may significantly alter the absorption of any
             drug substance including, but not limited to, any of the following: history of major
             gastrointestinal tract surgery, currently active inflammatory bowel syndrome.

         18. Evidence of clinically relevant pathology that in the investigator's opinion could
             interfere with the study results or put the subject's safety at risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry R Colca, PhD</last_name>
    <role>Study Director</role>
    <affiliation>MSDC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raj C. Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush Memorial University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush Memorial University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shah RC, Matthews DC, Andrews RD, Capuano AW, Fleischman DA, VanderLugt JT, Colca JR. An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease. Curr Alzheimer Res. 2014;11(6):564-73.</citation>
    <PMID>24931567</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2011</study_first_submitted>
  <study_first_submitted_qc>June 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2011</study_first_posted>
  <results_first_submitted>September 25, 2014</results_first_submitted>
  <results_first_submitted_qc>November 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 5, 2014</results_first_posted>
  <last_update_submitted>November 5, 2014</last_update_submitted>
  <last_update_submitted_qc>November 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>cognitive function</keyword>
  <keyword>brain glucose utilization</keyword>
  <keyword>FDG-PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MSDC-0160 Capsules</title>
          <description>MSDC tablets contained in #00 capsules
MSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo Capsules</title>
          <description>Placebo tablets contained in #00 capsules
Placebo: Placebo capsules given once daily for 90 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects completed the full study and are included in the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>MSDC-0160 Capsules</title>
          <description>MSDC tablets contained in #00 capsules
MSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo Capsules</title>
          <description>Placebo tablets contained in #00 capsules
Placebo: Placebo capsules given once daily for 90 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.3" spread="8.8"/>
                    <measurement group_id="B2" value="71.0" spread="8.0"/>
                    <measurement group_id="B3" value="71.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of an Apolipoprotein E e4 allele</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Apo E e4 allele present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apo E e4 allelle absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mini-Mental State Examination Score</title>
          <description>Screening Mini-Mental State Examination Score, Mean (SD). Possible scores range between 0 and 30. Scores ≥27 indicate normal cognition, 19-24 indicate mild impairment, 10-18 indicate moderate impairment, and scores ≤9 indicate severe impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.8" spread="2.4"/>
                    <measurement group_id="B2" value="25.2" spread="2.1"/>
                    <measurement group_id="B3" value="23.9" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum</title>
        <description>Investigate the effect of 150 mg daily MSDC-0160 vs placebo on 3-month change in brain glucose utilization using FDG-PET pre-specified regions of interest analysis referenced to cerebellum, including five bilateral regions: posterior cingulate, parietal cortex (angular gyrus), lateral temporal cortex, medial temporal cortex, and anterior cingulate-medial frontal cortex. Results are reported as Standardized Uptake Value Ratios. A change from baseline in the metabolic rate of glucose that is ≥0 indicates maintenance of brain glucose utilization, whereas values &lt;0 indicate a decline in brain glucose utilization.</description>
        <time_frame>Days 1(baseline) and 91</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>MSDC-0160 Capsules</title>
            <description>MSDC tablets contained in #00 capsules
MSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Placebo tablets contained in #00 capsules
Placebo: Placebo capsules given once daily for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum</title>
          <description>Investigate the effect of 150 mg daily MSDC-0160 vs placebo on 3-month change in brain glucose utilization using FDG-PET pre-specified regions of interest analysis referenced to cerebellum, including five bilateral regions: posterior cingulate, parietal cortex (angular gyrus), lateral temporal cortex, medial temporal cortex, and anterior cingulate-medial frontal cortex. Results are reported as Standardized Uptake Value Ratios. A change from baseline in the metabolic rate of glucose that is ≥0 indicates maintenance of brain glucose utilization, whereas values &lt;0 indicate a decline in brain glucose utilization.</description>
          <population>Intent-to-treat</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Posterior cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.03"/>
                    <measurement group_id="O2" value="-0.02" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parietal cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.02"/>
                    <measurement group_id="O2" value="-0.03" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lateral temporal cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.02"/>
                    <measurement group_id="O2" value="-0.02" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial temporal cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.02"/>
                    <measurement group_id="O2" value="-0.01" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ant. cing.-frontal cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.02"/>
                    <measurement group_id="O2" value="-0.03" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Global Cognitive Function Tests</title>
        <description>Change from baseline in cognitive function, as determined by global cognitive function on a neuropsychological battery of 19 tests, following 3 months treatment with MSDC-0160 versus placebo. A summary measure of global cognitive function was constructed by converting raw scores from 19 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort, Neuroepidemiology. 2005;25(4):163-175.</description>
        <time_frame>Days 1 (baseline) and 91</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MSDC-0160 Capsules</title>
            <description>MSDC tablets contained in #00 capsules
MSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Placebo tablets contained in #00 capsules
Placebo: Placebo capsules given once daily for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Global Cognitive Function Tests</title>
          <description>Change from baseline in cognitive function, as determined by global cognitive function on a neuropsychological battery of 19 tests, following 3 months treatment with MSDC-0160 versus placebo. A summary measure of global cognitive function was constructed by converting raw scores from 19 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort, Neuroepidemiology. 2005;25(4):163-175.</description>
          <units>z-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.11"/>
                    <measurement group_id="O2" value="0.03" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cognitive Function as Determined by the ADAS-Cog Subscale</title>
        <description>Alzheimer’s Disease Assessment Scale – Cognitive Subscale, an assessment of cognitive ability. Scores on 11 individual tasks were summed to produce the reported total score, with a possible range of 0 (no impairment) to 70 (severe impairment).</description>
        <time_frame>Days 1 (baseline) and 91</time_frame>
        <population>One subject in the MSDC-0160 group and 2 subjects in the placebo group were not able to complete the ADAS-Cog tests at both study time points.</population>
        <group_list>
          <group group_id="O1">
            <title>MSDC-0160 Capsules</title>
            <description>MSDC tablets contained in #00 capsules
MSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Placebo tablets contained in #00 capsules
Placebo: Placebo capsules given once daily for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cognitive Function as Determined by the ADAS-Cog Subscale</title>
          <description>Alzheimer’s Disease Assessment Scale – Cognitive Subscale, an assessment of cognitive ability. Scores on 11 individual tasks were summed to produce the reported total score, with a possible range of 0 (no impairment) to 70 (severe impairment).</description>
          <population>One subject in the MSDC-0160 group and 2 subjects in the placebo group were not able to complete the ADAS-Cog tests at both study time points.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="3.62"/>
                    <measurement group_id="O2" value="2.21" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cognitive Function as Estimate With the Executive Function Scale</title>
        <description>Estimate of the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale. A summary measure of executive function was constructed by converting raw scores from 9 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort, Neuroepidemiology. 2005;25(4):163-175.</description>
        <time_frame>Days 1 (baseline) and 91</time_frame>
        <population>One subject in the MSDC-0160 group and 2 subjects in the placebo group were not able to complete the executive function tests at both study time points.</population>
        <group_list>
          <group group_id="O1">
            <title>MSDC-0160 Capsules</title>
            <description>MSDC tablets contained in #00 capsules
MSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Placebo tablets contained in #00 capsules
Placebo: Placebo capsules given once daily for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cognitive Function as Estimate With the Executive Function Scale</title>
          <description>Estimate of the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale. A summary measure of executive function was constructed by converting raw scores from 9 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort, Neuroepidemiology. 2005;25(4):163-175.</description>
          <population>One subject in the MSDC-0160 group and 2 subjects in the placebo group were not able to complete the executive function tests at both study time points.</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.25"/>
                    <measurement group_id="O2" value="0.00" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HMW Adiponectin of MSDC-0160 or Placebo Over 12 Weeks</title>
        <description>Estimate the effect of 150 mg daily MSDC-0160 versus placebo on levels of high molecular weight adiponectin. Increases in HMW adiponectin suggest improved insulin sensitivity.</description>
        <time_frame>Days 1(baseline) and 91</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MSDC-0160 Capsules</title>
            <description>MSDC tablets contained in #00 capsules
MSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>Placebo tablets contained in #00 capsules
Placebo: Placebo capsules given once daily for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HMW Adiponectin of MSDC-0160 or Placebo Over 12 Weeks</title>
          <description>Estimate the effect of 150 mg daily MSDC-0160 versus placebo on levels of high molecular weight adiponectin. Increases in HMW adiponectin suggest improved insulin sensitivity.</description>
          <units>micromol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17822" spread="10940"/>
                    <measurement group_id="O2" value="795" spread="4477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Collection of safety data began in August 2011, when the first subject was randomized, and continued until March 19, 2013, when all 29 subjects had completed all study activities.</time_frame>
      <desc>Subjects were asked to report any adverse events during each study visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>MSDC-0160 Capsules</title>
          <description>MSDC tablets contained in #00 capsules
MSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo Capsules</title>
          <description>Placebo tablets contained in #00 capsules
Placebo: Placebo capsules given once daily for 90 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.o</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 14.0">Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.o</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Patent foramen ovale</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 14.0">QTcB elevation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoechoic nodule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in hip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cognitive decline, subjective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 14.0">Syncope, vasovagal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Scrotal varicose vein rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 14.0">Nose bleed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jerry Colca</name_or_title>
      <organization>Metabolic Solutions Development Company</organization>
      <phone>269.343.8732</phone>
      <email>jcolca@msdrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

